Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield Texas Prior Auth Policy Upd…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedBlue Cross Blue Shield - TexasPolicy N/A

    Prior authorization and vendor routing for advanced imaging and molecular genetic testing

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Texas policy alerts

    Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists CPT/HCPCS codes and service categories for which prior authorization may be required for Blue Cross Blue Shield of Texas members; affects providers requesting authorization for advanced imaging and related services. Applies to services managed by Carelon and other named vendors as indicated.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPrior authorization and vendor routing for advanced imaging and molecular genetic testing
    Policy CodePolicy N/A
    Change TypeSite-of-care additionsvendor routing updates
    Effective DateJan 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionProviders must contact Carelon at 1-866-455-8415 or via the Carelon website for prior authorization/management of the listed services.
    SourceLink
    POLICY UPDATE CHANGES

    Effective 01/01/2025, addition of site of care to the medical necessity criteria for multiple advanced imaging CPT codes.

    Update Category name from 'Non-Emergent Air Ambulance' to 'Medical Transportation' and changed services management from BCBSTX to Alacura for selected codes (with an exception for TRS Fully Insured Account: 212824 through 5/22/25).

    Multiple U-codes (0575U, 0576U, 0578U, 0582U, 0583U, 0585U, 0586U, 0592U, 0597U) and other molecular/genetic test codes are assigned to Alacura/Carelon for management with effective add dates (e.g., Add effective 1/1/2026).

    01/01/2025
    Site-of-care added
    CarelonManaged by vendor
    ~120+Codes with Carelon routing
    1/1/2026Future add dates noted
    1-866-455-8415Contact phone

    Coverage Criteria and Routing

    Prior authorization list (administrative)

    Prior authorization required for listed codes and updates:

    Authorization requirement: Prior authorization is required for the listed advanced imaging/radiology CPT codes as indicated; many codes are managed by Carelon with effective updates on 01/01/2025 and additions of site-of-care to medical necessity criteria.

    Providers must contact Carelon Medical Benefits Management for prior authorization/management as indicated in the code listings.

    Site-of-care additions (administrative)

    Site-of-care addition and Carelon routing

    Carelon routing and site-of-care requirement: For the listed CPT codes, services are handled by Carelon Medical Benefits Management and effective 01/01/2025 have addition of site of care to the medical necessity criteria.

    Providers must contact Carelon for prior authorization/medical necessity review.

    Carelon management requirement

    Management routing

    Carelon-managed tests: All listed CPT codes and associated molecular genetic tests in this section are to be managed through Carelon Medical Benefits Management.

    Providers must contact Carelon via phone (1-866-455-8415) or the Carelon website for management/authorization.

    Management requirement (informational)

    Services handled by Carelon

    Carelon-managed tests: Tests identified by the listed CPT codes are managed through Carelon Medical Benefits Management; contact Carelon for review/authorization as applicable.

    This excerpt lists code descriptors and vendor assignment; individual clinical medical necessity criteria are not included here.

    Panel composition + Carelon management

    Covered when testing meets panel composition and Carelon management requirements

    Carelon management and panel composition: Service is managed by Carelon Medical Benefits Management AND the genomic/panel test includes the minimum specified gene list or required duplication/deletion analyses for the indicated clinical syndrome (examples: 81410 panels require ≥9 genes for aortic dysfunction; 81413/81433 and others specify minimum gene counts per panel description).see code-specific thresholds (e.g., minimum gene counts) in code descriptions

    Providers must contact Carelon and supply documentation of panel composition (gene list, methods) when requesting authorization.

    Carelon-managed molecular genetic testing

    Codes listed in this section are identified as services handled by Carelon and have specific panel/gene content descriptions when provided.

    Carelon-managed molecular tests: The listed CPT/HCPCS/PLA codes correspond to molecular genetic or gene expression tests that are managed through Carelon Medical Benefits Management; providers must contact Carelon for authorization and management.

    Individual medical necessity criteria for each specific test are not provided in this extract — use code descriptions (panel size, gene content) and contact Carelon for review.

    The excerpt identifies code G0219 with the descriptor "PET Imaging Whole Body; Melanoma For Non-Covered Indications", indicating this specific PET whole‑body application is noted as a non‑covered example in the document fragment.

    The document shows reassignment of service management for selected medical transportation and related codes to third‑party vendors: effective 01/01/2025 the category name for non‑emergent air ambulance is updated to "Medical Transportation" and services A0430/A0435 transition from BCBSTX to Alacura (with an exception for TRS Fully Insured Account: 212824 until 5/22/25 and Alacura management effective 5/23/25). Several U‑code molecular testing entries are likewise assigned to Alacura/Carelon with additional effective dates noted (e.g., add effective 1/1/2026 for some U‑codes). Providers must follow the vendor routing specified for prior authorization and benefit management.

    Within the provided excerpt there are no explicit coverage exclusions or full medical necessity denial rules described; the section primarily lists molecular genetic CPT codes, brief test descriptors, and indicates that these services are handled by Carelon Medical Benefits Management for authorization and review.

    Multiple entries include retirement notices. Examples in the fragment show codes flagged with "Retire Effective" dates (for example, several 814xx entries include Retire Effective 04/01/2025 and other PLA/U codes such as J0428U and codes in the 0380U/0396U range are marked with retire effective dates). These retire notices indicate the listed code will be removed or superseded effective on the stated date.

    This document fragment does not state explicit coverage exclusions for the molecular genetic testing sections; instead it enumerates codes, minimum panel/gene composition requirements for some CPT panels, and notes that management/authorization is routed to Carelon for review.

    The listing for PLA/U codes includes a specific retirement notice for 0078U (Pain Management opioid‑use disorder genotyping panel), shown as "Retire Effective 07/01/2025" in the fragment.

    The excerpt contains multiple "Retire Effective" notices for select PLA/U codes across the molecular/genomic lists (examples include 0380U Retire Effective 04/01/2025, 0396U Retire Effective 07/01/2025, and J0428U Retire Effective 04/01/2025, among others), indicating several codes are scheduled for retirement on the dates stated.

    The provided excerpt contains extensive code listings and routing instructions to Carelon for prior authorization, but it does not include detailed medical necessity rule text or full clinical decision logic for individual tests — the fragment is administrative and descriptive rather than a complete set of medical necessity criteria.

    Several code lists are presented without an explicit coverage decision in the fragment; codes are mapped to test descriptors and to Carelon for management, but the excerpt itself does not contain the granular coverage determinations or clinical justification for each listed code.

    The fragment does not include any statements explicitly labeled "Not Medically Necessary"; instead the document lists codes and indicates that Carelon manages prior authorization and reviews for those services.

    Reiterating the same point for clarity: the excerpted sections contain code listings and vendor routing instructions but do not present explicit not‑medically‑necessary determinations within the provided text.

    Code Listings and Descriptions

    Covered CPT/HCPCS codes routed to Carelon or BCBSTXmixed
    73722Magnetic Resonance (eg proton) Imaging Any Joint Of Lower Extremity; With Contrast Material(s)
    73723Magnetic Resonance (eg proton) Imaging Any Joint Of Lower Extremity; Without Contrast Material(s) Followed By Contrast Material(s) And Further Sequences
    73725Magnetic Resonance Angiography Lower Extremity With Or Without Contrast Material(s)
    74150Computed Tomography Abdomen; Without Contrast Material
    74160Computed Tomography Abdomen; With Contrast Material(s)
    74170Computed Tomography Abdomen; Without Contrast Material Followed By Contrast Material(s) And Further Sections
    74174Computed Tomographic Angiography Abdomen And Pelvis With Contrast Material(s) Including Noncontrast Images If Performed And Image Postprocessing
    74175Computed Tomographic Angiography Abdomen With Contrast Material(s) Including Noncontrast Images If Performed And Image Postprocessing
    74176Computed Tomography Abdomen And Pelvis; Without Contrast Material
    74177Computed Tomography Abdomen And Pelvis; With Contrast Material(s)
    1–10 of 197
    1/20
    Molecular/Genomic PLA, Temp, and U-codes routed to Carelonmixed
    81205See molecular genetic code list (BRCA and others)
    81208See molecular genetic code list
    81209See molecular genetic code list
    81210See molecular genetic code list
    81212See molecular genetic code list
    81215See molecular genetic code list
    81216See molecular genetic code list
    81217See molecular genetic code list
    81218See molecular genetic code list
    81221See molecular genetic code list
    1–10 of 73
    1/8
    Additional molecular/genomic and U/PLA codesmixed
    0016MSee source
    0016USee source
    0017MSee source
    0017USee source
    0018UOncology RNA whole-transcriptome sequencing — see policy
    0019UOncology RNA whole-transcriptome sequencing — see policy
    0022UTargeted genomic sequence analysis panel — see policy
    0023UOncology AML genotyping — see policy
    0026USee source
    0027USee source
    1–10 of 24
    1/3

    Provider Responsibilities and Authorization Steps

    Denial Risk

    Coverage and Denial Risk / How to Initiate Authorization

    Prior authorization is required for many services listed in this document. Presence of a code on this list does not guarantee coverage under the member's benefit contract; failure to obtain required prior authorization may result in claim denial. Providers must verify member benefits and obtain authorization per the routing rules below before scheduling or performing services.

    • The presence of a code on this list does not indicate coverage — consult member benefits.
    • Failure to obtain required prior authorization may risk claim denial.
    Prior Authorization

    Carelon Prior Authorization Routing and Contact

    Services that are managed by Carelon Medical Benefits Management require prior authorization via Carelon. Providers must contact Carelon by phone at 1-866-455-8415 or via the Carelon website (https://careloninsights.com/medical-benefits_management/specialty-care) to initiate or obtain prior authorization for routed services.

    Contrast and Imaging Technique Notes

    Billing Rule

    Prior authorization applies regardless of contrast specification

    Prior authorization applies regardless of contrast usage for the listed imaging CPT codes; the policy lists each code with its contrast specification (without, with, or without then with contrast).

    Billing Rule

    Include contrast usage details when submitting authorizations

    Many CPT descriptions explicitly indicate 'With or Without Contrast' or sequences 'Without then With Contrast'; providers should include contrast details in authorization requests as shown in code descriptors.

    Definitions and Vendor Identifiers

    Carelon — Carelon Medical Benefits Management vendor identifier
    Carelon — vendor identifierCarelon Medical Benefits Management is the designated vendor for prior authorization/management of many listed services; providers should contact Carelon at 1-866-455-8415 or via careloninsights.com/medical-benefits_management/specialty-care
    S92xx / S93xx series — home infusion therapy per-diem codes definition
    S92xx / S93xx series meaningS92xx/S93xx are home infusion therapy per‑diem HCPCS codes covering catheter care maintenance and related home infusion services
    Per‑diem scopeThese S‑codes include administrative services, pharmacy professional services, care coordination, supplies and equipment; drugs and nursing visits coded separately
    Routing/handling noteHome infusion per‑diem S‑codes in the excerpt are routed to BCBSTX for management per the document

    Background and Context

    This fragment of the background highlights that the document primarily contains code descriptors and administrative handling assignments. It includes codes for home infusion per‑diem services (S‑series), medical transportation (A0430/A0435) with vendor reassignment to Alacura, and numerous molecular genetic PLA/U/CPT codes with descriptors and management routing to Carelon for prior authorization.

    Not Covered Examples

    As an example of not‑covered content in the fragment, G0219 is described as "PET Imaging Whole Body; Melanoma For Non‑Covered Indications." The excerpt also shows that many PET, nuclear medicine, and molecular testing codes are routed to Carelon for management; providers should confirm coverage under the member's benefits and obtain any required prior authorization through the vendor pathways noted.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyPrior authorization and vendor routing for advanced imaging and molecular genetic testing
    Policy CodePolicy N/A
    Change TypeSite-of-care additionsvendor routing updates
    Effective DateJan 1, 2025
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionProviders must contact Carelon at 1-866-455-8415 or via the Carelon website for prior authorization/management of the listed services.
    SourceLink
    On This Page
    Coverage Criteria and RoutingCode Listings and DescriptionsProvider Responsibilities and Authorization StepsContrast and Imaging Technique NotesDefinitions and Vendor IdentifiersBackground and ContextNot Covered Examples
    • Carelon phone: 1-866-455-8415
    • Carelon website: https://careloninsights.com/medical-benefits_management/specialty-care
    • Claims for services routed to Carelon (advanced imaging, cardiology, nuclear medicine, PET/SPECT, molecular genetic testing, etc.) are subject to Carelon review prior to payment.
    Note

    BCBSTX and Vendor Routing / Site-of-Care Updates

    Certain codes and service categories continue to be handled by Blue Cross Blue Shield of Texas (BCBSTX) or other vendors. For services assigned to BCBSTX (for example selected ENT/cochlear device replacement components and specific therapeutic apheresis codes), follow BCBSTX authorization processes shown on the member ID card or the BCBSTX provider resources. For medical transportation and related services, management has transitioned to Alacura (see vendor/exceptions notes) — verify routing before requesting authorization.

    • BCBSTX-managed examples: L8615–L8619 device/component codes and select procedure codes (see list).
    • Alacura now manages many Medical Transportation codes (A0430, A0435, etc.) — exceptions apply (TRS Fully Insured account 212824 through 5/22/25).
    • Verify vendor routing (Carelon, BCBSTX, Alacura) for each code prior to submission.
    Note

    Document Vendor / Exception Identifiers and Service-Management Changes

    Service management assignments and exceptions (vendor identifiers, account-level exceptions, service-management changes) are documented in the code list. Providers must check the management assignment for each code and note any account-level exceptions (for example TRS Fully Insured Account: 212824) that affect where to route prior authorization requests.

    • Document vendor/exception identifiers (e.g., Carelon, BCBSTX, Alacura) before requesting authorization.
    • Service management changes (example: medical transportation moved from BCBSTX to Alacura) may change prior authorization routing — verify the current manager and effective dates.
    • Account-level exceptions (TRS Fully Insured Account: 212824) are noted on the list — follow those exception instructions.
    Documentation Required

    Panel Composition and Documentation Requirements

    Molecular and genomic test panels that require prior authorization via Carelon must include documentation of panel composition when specified. Where the policy requires a minimum gene list (for example certain genomic sequence panels), include the panel gene list and methodology with the authorization request.

    • When panel composition is specified, include the minimum gene list in the authorization documentation (examples: 81410, 81441, 81442 panels).
    • Provide assay methodology and specimen type when requested.
    • Carelon may require additional clinical documentation to determine medical necessity for complex genomic tests.
    Note

    Service Changes, Effective Dates, and Code Retirement

    Prior authorization requirements and routing can change over time. Providers should confirm the effective dates and retirement notes in the code list (for example: code 0078U is noted as retiring effective 07/01/2025) and verify current routing before submitting authorization requests.

    • Code retirement note: 0078U — retire effective 07/01/2025.
    • Check the 'Updates' or effective date column for each code to confirm current management and prior authorization requirements.
    • If service management changes (e.g., transition to Alacura or Carelon), follow the new routing instructions beginning on the stated effective date.
    A0430/A0435 and 0575U-0597U series — non-emergent air ambulance/medical transportation and U-codes for molecular genetic tests
    A0430 / A0435 — medical transportationA0430 (fixed wing transport one way) and A0435 (fixed wing air mileage) are classified as Medical Transportation (formerly Non‑Emergent Air Ambulance)
    U-code series for molecular tests0575U–0597U series in the excerpt are molecular genetic test U‑codes mapped alongside transportation entries in the vendor assignment section
    Vendor assignment noteA0430/A0435 assigned to Alacura; selected U‑codes receive 'Add effective' dates for Carelon/Alacura management
    Molecular Genetic Lab Testing — definition and scope
    Definition — Molecular Genetic Lab TestingTesting that analyzes specific genes or genomic regions to detect variants including common variants, full gene sequencing, duplication/deletion analysis, translocation analysis, repeat expansion characterization, and cytogenomic microarray/optical genome mapping as specified per CPT code descriptions
    Scope — specimen and methodsIncludes analysis of FFPE tumor tissue, plasma cell‑free DNA, blood, saliva, and embryonic specimens using methods such as NGS, RT‑PCR, microarray, FISH, and OGM
    Report formatsResults may include variant identification, copy number changes, tumor mutational burden, microsatellite instability, and algorithmic risk scores as described per test code
    Molecular Genetic Lab Testing — additional definition reference
    Molecular Genetic Lab Testing (term)The document uses 'Molecular Genetic Lab Testing' to group gene‑focused assays and provides code‑specific descriptions and routing to Carelon for management
    Clinical examples includedExamples across CPT/PLA codes include single‑gene analyses, multi‑gene panels, whole exome/genome sequencing, MRD assays, and gene expression profiling
    Molecular Pathology Procedure Levels (81400–81405) — Levels 1–6 definitions
    Molecular Pathology Procedure Levels (81400–81405)Levels 1–6 correspond to increasing complexity: Level 1 identification of a single germline variant through techniques like melt curve analysis; Level 2 covers 2–10 SNPs or targeted non‑sequencing analyses; Levels 3–6 include larger targeted analyses, exon‑level sequencing, and regional cytogenomic analyses as described for CPT 81400–81405
    Examples of Level applicationsLevel descriptions include examples: Level 4 may include single‑exon sequencing or >10 amplicons multiplex PCR; Level 6 includes analysis of 6–10 exons or regional cytogenomic analysis
    Genomic sequence analysis panel — definition and minimum gene count requirement concept
    Genomic sequence analysis panel — conceptA genomic sequence analysis panel is a multi‑gene sequencing test that must include sequencing of a specified minimum number of genes for the indicated clinical syndrome (document lists minimum gene counts per panel)
    Documentation requirementProviders must document the included gene list and panel composition when submitting for review/authorization (panel composition documentation referenced in guidance)
    Genomic sequence analysis panel examples (CPT 81441-81464)
    CPT genomic panel examples (81441–81464)CPT examples include 81441 (inherited bone marrow failure syndromes, ≥30 genes), 81442 (Noonan spectrum disorders, ≥12 genes), 81462–81464 (solid organ neoplasm cfDNA panels), and multiple other 8144x–8146x panels described in the section
    Panel purposesThese CPT examples cover inherited disorders, cancer profiling, hearing loss, tumor cfDNA assays, and other clinical indications as listed
    mRNA gene expression profiling — CPT examples and definition
    mRNA gene expression profiling examplesCPT examples include 81518–81529 series and 81540/81541 etc.; examples in the document: 81558 (139‑gene transplant blood profile, add effective 04/01/2025), 81595 (heart transplant 20‑gene qPCR profile), and 81504 (microarray 2000 genes for tissue of origin)
    MethodologiesmRNA profiling methods include RT‑PCR, microarray, and NGS‑based whole transcriptome assays depending on the code
    Carelon Medical Benefits Management — vendor description
    Carelon role — vendor descriptionCarelon Medical Benefits Management is the designated third‑party medical benefits manager referenced for prior authorization and management of specialty molecular genetic testing and many advanced imaging services; contact: 1‑866‑455‑8415 or careloninsights.com/medical‑benefits_management/specialty‑care
    When to contact CarelonProviders must contact Carelon for management/authorization of listed CPT/PLA/U codes as indicated in the document
    Targeted genomic sequence analysis / comprehensive genomic profiling — definition
    Targeted genomic sequence analysis / comprehensive genomic profiling — definitionDescribed tests interrogate single‑nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor mutational burden and microsatellite instability using FFPE tissue or cell‑free DNA as specified per code
    Clinical outputsReports may include variant calls, CNVs, rearrangements, TMB, MSI and therapy‑relevant associations depending on the assay
    Whole genome / whole exome sequencing — definition
    Whole genome / whole exome sequencing — definitionComparative sequencing of paired malignant and normal DNA or exome specimens (fresh or FFPE tissue, blood, or bone marrow) for variant identification; includes whole transcriptome sequencing and optical genome mapping where specified
    Use casesUsed for pan‑tumor profiling, rare disease diagnosis, and comparator genome analyses (eg proband plus parents/siblings) as noted in codes 0297U–0299U and related entries
    Molecular Genetic Lab Testing / PLA codes — PLA/proprietary code definition
    PLA / proprietary code definitionPLA (proprietary/temporary) codes represent specific molecular/genomic assays described by gene panel content, methodology, specimen type and report format (examples: 0314U, J0400U, J0454U)
    PLA handlingPLA codes in the document are routed to Carelon for benefits management/authorization and are listed with code‑level descriptions
    Molecular genetic lab testing PLA/unique codes — examples
    PLA / unique code examplesExamples of PLA/unique codes listed: J0454U, 0466U, 0473U, 0474U, 0475U, J0469U, 00471U — each corresponds to a specific molecular/genomic assay with accompanying clinical description
    Range and purposePLA codes cover oncology, rare diseases, pharmacogenomics, transplant and prenatal testing among other specialty areas
    Carelon Medical Benefits Management — contact/role definition
    Carelon contact / roleCarelon Medical Benefits Management: contact phone 1‑866‑455‑8415 and careloninsights.com/medical‑benefits_management/specialty‑care for prior authorization and specialty benefits management
    Provider routing instructionProviders must route prior authorization requests for listed services to Carelon when the code listing indicates Carelon handling